Pieris Pharmaceuticals

Pieris Pharmaceuticals is a biotechnology company based in Boston, Massachusetts. Pieris develops 4-1BB bispecifics immuno-oncology assets. The company's business model involves partnering with pharmaceutical companies for development, regulatory, and sales-based milestones, as well as potential sales royalties. Pieris targets pharmaceutical companies and investors seeking innovative oncology treatments. Its geographic coverage is global, and sales channels include partnerships. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS. Pieris Pharmaceuticals www.pieris.com

Palvella Therapeutics is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel therapies for individuals with rare genetic skin diseases. Established in 2015, the company's headquarters are located in Wayne, Pennsylvania. Palvella Therapeutics operates with a mission to provide solutions for patients who currently lack FDA-approved treatments. The company's operations are focused on the healthcare, biotechnology, and pharmaceutical industries. Palvella Therapeutics is dedicated to serving patients and is driven by innovation and a commitment to rare disease research. Palvella Therapeutics is led by a team of experienced professionals. Wes Kaupinen serves as the President and CEO, while Matthew E. Korenberg holds the position of Chief Financial Officer. The Chief Scientific Officer is Jeff Martini, Ph.D., and Kathy Goin is the Chief Operating Officer. Jason Burdette is the SVP of CMC and Technical Operations, and Emily Cook is the SVP of Clinical Operations. Bohan Wei serves as the VP of Corporate Development and New Product Planning. Additionally, Braham Shroot, Ph.D., is a Senior Technical Advisor. Palvella Therapeutics possesses several competitive advantages. The company benefits from over 20 years of entrepreneurial life sciences experience. It also has a proven track record of success in developing and commercializing novel therapies. Furthermore, the company has strong leadership and scientific management teams. Palvella Therapeutics utilizes a revolutionary drug delivery platform called QTORIN™. The company's values include serving patients, innovation, and a commitment to rare disease research. Palvella Therapeutics can be contacted via email at [email protected] or by mail at 125 Strafford Avenue, Suite 360 Wayne, PA 19087.